Risks

High net debt to EBITDA versus many medtech peers leaves ITGR more exposed to refinancing and rate pressure, constraining flexibility if demand softens.

Interest coverage is adequate but not robust versus stronger peers, so margin compression or volume volatility could more quickly pressure covenant headroom.

A long cash conversion cycle driven by elevated inventory and receivables ties up working capital, limiting peer-relative ability to absorb shocks or fund growth.

Exposure to hospital and procedure timing remains a sector risk, and ITGR’s leverage makes any demand delay more consequential than for less levered peers.

Opportunities

ITGR’s current ratio and quick ratio are well above typical medtech peers, supporting better liquidity positioning if end-market demand becomes uneven.

The company’s working-capital profile can improve if inventory normalizes, creating cash release potential that is more visible than for peers with tighter liquidity.

As a diversified medical technology supplier, ITGR can benefit from steady procedure-related demand that is generally less cyclical than broader industrial peers.

If operating performance holds, deleveraging could outpace peers from a higher starting liquidity base, improving strategic flexibility over the next several years.

Overall Score

ITGR’s strong liquidity and resilient medtech demand support forward positioning, but elevated leverage and working-capital intensity remain the main peer-relative constraints.